This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Nasal Inhalation Testing: IPAC-RS Droplet Size Analysis
Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Nasal Drug Delivery: In Vitro Anatomical Models
Publications, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions
Aptar Pharma Discusses Intranasal Drug Delivery with PharmTech
Podcasts, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
Nasal Spray Orientation & Sumatriptan Exposure using PK Modelling
Publications, Pharmaceutical, Product Solutions, Drug Delivery Innovations, Brand Differentiation, Market Insights
